# Alliance for Clinical Trials in Oncology

Source: https://onco.cc/companies/alliance-oncology/  
OnCo record `alliance-oncology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

US cooperative group formed from CALGB, ACOSOG, and NCCTG; running OptimICE-pCR, which asks whether TNBC patients with a complete response still need a year of immunotherapy.

## Summary

The Alliance for Clinical Trials in Oncology, based in Chicago, is the US cooperative group formed in 2011 from CALGB, ACOSOG and NCCTG, and a member of the NCI National Clinical Trials Network. Its trials include CALGB 40603, which tested carboplatin in triple-negative breast cancer, Z0011, which showed sentinel node biopsy could replace axillary dissection in selected patients, and A012103, the OptimICE-pCR trial asking whether TNBC patients with a pathologic complete response still need a year of pembrolizumab; ATOMIC and CABINET are also in OnCo, with Alan P. Venook and Evanthia Galanis among the people linked. OnCo connects it to bottlenecks on slow enrolment and the exclusion of older patients, and to ideas for a permanent surgical trials network. Whether de-escalation trials can recruit when the default is more treatment is its standing question. Its programmes are listed in the notes.

## Fields

- Kind: Company
- Last checked: 2026-09-06
- Also known as: Alliance; Cancer and Leukemia Group B; CALGB; Alliance Foundation Trials; ACOSOG; NCCTG
- Tags: cooperative-group
- HQ: Chicago, IL
- Type: cooperative-group
- Website: https://www.allianceforclinicaltrialsinoncology.org

## Notes

- NCTN cooperative group
- OptimICE-pCR
- Breast surgical de-escalation (Z0011)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Alliance_for_Clinical_Trials_in_Oncology
- Official website: https://www.allianceforclinicaltrialsinoncology.org

## Connected records

- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Craniopharyngioma](https://onco.cc/cancers/craniopharyngioma/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Sentinel lymph node biopsy](https://onco.cc/technologies/sentinel-node/)
- institutions: [Duke Cancer Institute](https://onco.cc/institutions/duke-cancer-institute/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- trials: [ACOSOG Z0011 (Alliance)](https://onco.cc/trials/acosog-z0011/), [ACOSOG Z1071 (Alliance)](https://onco.cc/trials/acosog-z1071/), [ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)](https://onco.cc/trials/alchemist/), [Alliance A021501](https://onco.cc/trials/alliance-a021501/), [Alliance A021806](https://onco.cc/trials/alliance-a021806/), [Alliance A071401](https://onco.cc/trials/a071401/), [Alliance N0147](https://onco.cc/trials/n0147/), [Alliance N0574 (NCCTG N0574)](https://onco.cc/trials/alliance-n0574/), [ATOMIC (Alliance A021502)](https://onco.cc/trials/atomic/), [BWEL (Breast Cancer Weight Loss, Alliance A011401)](https://onco.cc/trials/bwel/), [CABINET (Alliance A021602)](https://onco.cc/trials/cabinet/), [CALGB 140503 (Alliance)](https://onco.cc/trials/calgb-140503/), [CALGB 40603 (Alliance)](https://onco.cc/trials/calgb-40603/), [CALGB 90401](https://onco.cc/trials/calgb-90401/), [CALGB 9343](https://onco.cc/trials/calgb-9343/), [CALGB/SWOG 80405](https://onco.cc/trials/calgb-80405/), [CODEL](https://onco.cc/trials/codel/), [COMET (Comparison of Operative versus Monitoring and Endocrine Therapy)](https://onco.cc/trials/comet-dcis/), [Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer](https://onco.cc/trials/nct06632327/), [Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer](https://onco.cc/trials/nct00077311/), [Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer](https://onco.cc/trials/nct04137107/), [I-SPY 1 (CALGB 150007/150012, ACRIN 6657)](https://onco.cc/trials/i-spy-1/), [Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia](https://onco.cc/trials/nct03150693/), [Lung-MAP (SWOG S1400 and S1900)](https://onco.cc/trials/lung-map/), [OptimICE-pCR (A012103)](https://onco.cc/trials/optimice-pcr/), [Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer](https://onco.cc/trials/nct00343382/), [Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer](https://onco.cc/trials/nct01086605/), [PROSPECT (Alliance N1048)](https://onco.cc/trials/prospect/), [RATIFY (CALGB 10603)](https://onco.cc/trials/ratify/), [Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer](https://onco.cc/trials/nct00026117/), [Talc in Treating Patients With Malignant Pleural Effusion](https://onco.cc/trials/nct00002622/), [Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage](https://onco.cc/trials/nct05610163/), [Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial](https://onco.cc/trials/nct05673148/), [Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer](https://onco.cc/trials/nct05710406/), [The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06115499/), [TIGER: standard-dose TIP versus high-dose TI-CE with stem cell transplant as first salvage for relapsed germ cell tumours](https://onco.cc/trials/tiger-trial/), [Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer](https://onco.cc/trials/nct04094688/)
- key papers: [Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations](https://onco.cc/key-papers/paper-a071401-brastianos-jco-2023/), [Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405)](https://onco.cc/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/), [Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on](https://onco.cc/roadmaps/trial-modernisation-roadmap/)
- people: [Alan P. Venook](https://onco.cc/people/alan-venook/), [Evanthia Galanis](https://onco.cc/people/evanthia-galanis/)
- bottlenecks: [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [Trials enrol too few, too slowly](https://onco.cc/bottlenecks/b-trial-enrolment/)
- ideas: [A permanently funded international network for randomised cancer surgery trials](https://onco.cc/ideas/idea-fund-surgical-trials-network/), [A statutory minimum share of public trial money for surgery and radiotherapy](https://onco.cc/ideas/idea-fund-non-drug-trial-quota/)
- companies: [Austrian Breast & Colorectal Cancer Study Group](https://onco.cc/companies/abcsg/), [ETOP IBCSG Partners Foundation](https://onco.cc/companies/etop-ibcsg/)

---
JSON: https://onco.cc/api/v1/entities/alliance-oncology.json